Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Rheum Dis ; 72(3): 453-6, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23264357

ABSTRACT

BACKGROUND: The soluble form of the interleukin 7 receptor (sIL-7R) is produced by fibroblasts after stimulation with proinflammatory cytokines. Increased sIL-7R serum and synovial fluid levels were recently demonstrated in patients with rheumatoid arthritis. OBJECTIVES: To investigate whether sIL-7R production is dysregulated in systemic lupus erythematosus (SLE), and whether this correlates with disease activity. METHODS: Serum and urine sIL-7R concentrations were measured by ELISA, and sIL-7R quantitative PCR (qPCR) studies were performed in peripheral blood mononuclear cells (PBMCs). IL-7R, tumour necrosis factor α (TNFα), IL-1ß and IL-17 immunostainings were performed on kidney sections. RESULTS: sIL-7R concentrations were significantly higher in SLE sera than in controls, and correlated with SLE Disease Activity Index (SLEDAI) scores. Accordingly, serum sIL-7R levels were strongly raised in patients with nephritis. Moreover in patients with lupus nephritis, serum sIL-7R decreased upon treatment. sIL-7R gene expression in PBMCs was similar in patients with lupus nephritis and controls. By contrast, abundant perivascular IL-7R expression was seen in SLE kidney biopsy specimens, which was associated with expression of TNFα in the surrounding tissue. CONCLUSIONS: Our data indicate that sIL-7R is a marker of SLE disease activity, especially nephritis. In contrast to conventional disease activity markers, sIL-7R is not produced by immune cells, but might instead reflect activation of tissue cells in the target organ.


Subject(s)
Lupus Nephritis/blood , Receptors, Interleukin-7/blood , Adult , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/complications , Male , Reverse Transcriptase Polymerase Chain Reaction
2.
Autoimmun Rev ; 12(5): 617-28, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23232124

ABSTRACT

Systemic Lupus Erythematosus (SLE) is a clinically diverse, chronic autoimmune disease with inflammation in several organ systems. Its pathogenesis is complex, but includes many factors that can be influenced by glucocorticoids (GCs). Indeed, GCs constitute the corner-stone in SLE-treatment. However, guidelines for GC-treatment of the different disease manifestations are lacking and not every patient responds (sufficiently). The focus of this systematic review is to evaluate the differential glucocorticoid treatment of various SLE manifestations. In addition, some relevant mechanisms of glucocorticoid action as well as resistance are discussed.


Subject(s)
Glucocorticoids/standards , Glucocorticoids/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Adaptive Immunity/drug effects , Autoantibodies/biosynthesis , Autoantibodies/physiology , Autoantigens/immunology , Drug Tolerance/immunology , Glucocorticoids/administration & dosage , Humans , Immunity, Cellular/drug effects , Immunity, Innate/drug effects , Lupus Erythematosus, Systemic/etiology , Lupus Erythematosus, Systemic/pathology , Self Tolerance/drug effects
3.
Ann Rheum Dis ; 66(7): 865-70, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17329307

ABSTRACT

BACKGROUND: Systemic lupus erythematosus (SLE) is associated with a high prevalence of cardiovascular disease. Circulating endothelial progenitor cells (EPCs) contribute to vascular regeneration and repair, thereby protecting against atherosclerotic disease. EPCs are derived from CD34+ haematopoietic stem cells (HSCs), which have an increased propensity for apoptosis in the bone marrow of patients with SLE. AIM: To determine whether circulating HSCs and EPCs are reduced in SLE, contributing to an increased cardiovascular risk. METHODS: Progenitor cells were sampled from 15 female patients with SLE in prolonged clinical remission from their disease and 15 matched healthy controls. HSC and CD34+KDR+ EPCs were quantified by flow cytometry. Annexin V staining was used to identify apoptotic cells. RESULTS: Patients with SLE had reduced levels of circulating CD34+ HSCs and CD34+KDR+ EPCs, associated with increased HSC apoptosis. Compared with controls, the fraction of HSCs that could be identified as EPCs was higher in patients with SLE, consistent with a primary defect of HSCs. EPC outgrowth from mononuclear cells, which depends mainly on CD34- cells, was unaffected. CONCLUSIONS: Patients with SLE have lower levels of circulating HSCs and EPCs, even during clinical remission. The data suggest that increased HSC apoptosis is the underlying cause for this depletion. These observations indicate that progenitor cell-mediated endogenous vascular repair is impaired in SLE, which may contribute to the accelerated development of atherosclerosis.


Subject(s)
Endothelial Cells/pathology , Hematopoietic Stem Cells/pathology , Lupus Erythematosus, Systemic/blood , Adult , Anti-Inflammatory Agents/therapeutic use , Antigens, CD34/physiology , Apoptosis/physiology , Arteries/physiopathology , Blood Cell Count , Cells, Cultured , Female , Humans , Leukocytes, Mononuclear , Lupus Erythematosus, Systemic/physiopathology , Prednisone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...